LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 631 participants.

Also called NCT01380730

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 631 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
  • The TIMI Study Group Registry lists this organization as a collaborator
Registry
  • NCT NCT01380730
Other papers using this trial's data
  • AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial Circulation, 2013-08-27 DOI, PubMed 23884353

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, Denmark, Hungary (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01380730. Randomized; quadruple masking; primary purpose treatment. Start 2011-07-01 (actual); primary completion 2012-04-05 (actual). Results posted on 2015-10-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy
Acronym
LAPLACE
Condition
Hyperlipidemia
Intervention (Biological)
Evolocumab
Intervention (Other)
Placebo to Evolocumab
Lead sponsor
Amgen (class: industry)
Collaborator
The TIMI Study Group (class: other)

Record details

Record id
cardio:ct-nct01380730
Content hash
93215bcbe9af51b40ccc4e3fe5a56a4499216032f770d2e5fe3d55982f85b92d